Korsana Biosciences, Inc.
Research Korsana Biosciences, Inc. (KRSA) on Bullrun: market cap USD 18.88M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKRSA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 18.88M
- Financial periodQ3 2026
- Net income-USD 46.43M
- Free cash flow-USD 47.06M
Valuation Snapshot
latest market cap is USD 18.88M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 35.64M | -USD 22.41M | n/a | -1.11 | USD 154.14M | n/a | -USD 33.97M |
| FY2024 | USD 0 | -USD 88.00K | USD 44.00K | n/a | -0.02 | USD 10.11M | n/a | USD 66.00K |
| FY2023 | USD 0 | -USD 5.26M | n/a | n/a | -2.25 | USD 7.57M | n/a | USD 11.29M |
| FY2022 | USD 297.00K | -USD 44.08M | -USD 40.61M | n/a | -20.28 | USD 13.38M | USD 3.50M | USD 10.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 18.88M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.20M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 8.19M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 28.53M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 74.67M | n/a | n/a | n/a |
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Korsana Biosciences, Inc.'s market cap?
Korsana Biosciences, Inc.'s market capitalization is USD 18.88M.
What does Korsana Biosciences, Inc. do?
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders.